Chen C Y, Han F, Zhao C, Lu L X, Sun Y, Liu X F, Lu T X
Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, People's Republic of China.
Br J Radiol. 2009 Jun;82(978):452-8. doi: 10.1259/bjr/72813246.
The aim of this study was to investigate the outcome in 556 patients with locally advanced nasopharyngeal carcinomas treated by radiation therapy alone. We observed 556 patients with stage T3-4 and N0-3 carcinoma who were treated by conventional radiotherapy alone between January and December 1999. The total dose delivered to the nasopharynx was 66-80 Gy over 6.5-8 weeks and to the neck lymph nodes 60-70 Gy over 6-7 weeks. The 5-year actuarial overall survival rate (OS) reached 66.41%. The OS was higher among stage T3 patients than among stage T4 patients (69.12% vs 58.96%, p = 0.0359). Among patients with stage N0, N1, N2 and N3 disease, the OS was 73.98%, 65.96%, 57.58% and 29.39%, respectively (p = 0.0009). Differences in disease-free survival, locoregional control rate and metastasis-free survival rate among each N stage were statistically significant, although this was not true of differences between stage T3 and T4 disease. Multivariate analysis showed that gender, age, T stage and N stage were significant prognostic factors for 5-year overall survival, disease-free survival, locoregional control and metastasis-free survival. We found that N stage is the dominant prognostic indicator for patients with locally advanced nasopharyngeal carcinoma receiving conventional radiation therapy alone, and that T stage was only a secondary correlative factor.
本研究旨在调查556例仅接受放射治疗的局部晚期鼻咽癌患者的治疗结果。我们观察了556例T3 - 4期和N0 - 3期的癌患者,他们于1999年1月至12月期间仅接受了常规放疗。鼻咽部的总剂量在6.5 - 8周内给予66 - 80 Gy,颈部淋巴结在6 - 7周内给予60 - 70 Gy。5年精算总生存率(OS)达到66.41%。T3期患者的总生存率高于T4期患者(69.12%对58.96%,p = 0.0359)。在N0、N1、N2和N3期疾病的患者中,总生存率分别为73.98%、65.96%、57.58%和29.39%(p = 0.0009)。尽管T3期和T4期疾病之间的差异并非如此,但各N分期之间的无病生存率、局部区域控制率和无转移生存率差异具有统计学意义。多变量分析显示,性别、年龄、T分期和N分期是5年总生存、无病生存、局部区域控制和无转移生存的重要预后因素。我们发现,N分期是仅接受常规放疗的局部晚期鼻咽癌患者的主要预后指标,而T分期只是次要相关因素。